The cell therapy area at 3P Biopharmaceuticals receives GMP certification of an allogeneic cell therapy medicine

by 3P Biopharmaceuticals

This past April, 3P Biopharmaceuticals obtained GMP (Good Manufacturing Practices) certification for a manufacturing process of a cellular medication destined for allogeneic therapy treatments

Read more

3P Biopharmaceuticals keeps focused in international markets

by 3P Biopharmaceuticals

With more than 60% of its portfoloio composed of international clients, 3P has active presence in major international markets such as USA, Australia, Mexico, Argentina, France, Norway, Italy, UK, Belg...

Read more

3P Biopharmaceuticals Advanced Therapy area develops a GMP buffer involved in a novel treatment for the Age-Related Macular Degeneration (AMD)

by 3P Biopharmaceuticals

The project has received funding from the European Union’s Seventh Framework Programme and aims to develop a non-viral gene therapeutic approach for the treatment of this neurodegenerative disease o...

Read more

How to select the perfect partner, next CPhI 2015 by 3PBiopharmaceuticals, Charles River, Covance and Menarini Biotech

by 3P Biopharmaceuticals

"The challenge of Partner selection: the best travel companion in biologics drug development adventure” will discover the keys to success in this major challenge

Read more

EU-ToxRisk: proyecto europeo líder para evaluar el riesgo y toxicidad de la exposición a medicamentos y productos químicos

by Instituto de Investigación Sanitaria La Fe

El proyecto EU-ToxRisk, coordinado por Bob van de Water, catedrático de Toxicología en la Universidad de Leiden (Holanda), busca convertirse en el líder europeo en evaluación de la seguridad quím...

Read more

Kymos crece con la biotec

by La Vanguardia

Kymos realiza controles de calidad de medicamentos o de sus componentes, estudios de bioequivalencia, estudios de estabilidad para determinar la caducidad o, en investigación, análisis de muestras d...

Read more

InKemia refuerza su participación en Recerca Clínica hasta el 51% del capital

by InKemia IUCT group

InKemia informa que el grupo ha realizado la compra de las participaciones del segundo mayor accionista de Recerca Clínica, S.L. por valor de 75.000 euros. Así mismo suscribe una ampliación de capi...

Read more
Subscribe to Directory
Write an Article

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Nace la red española de ensayos clínic...

by Vall d’Hebron

Está compuesta por los principales centros hospitalarios y redes pedi...

Photos Stream